Valeant Pharmaceuticals

valeant.com

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical and medical device company that develops, manufactures and markets a broad range of prescription and non-prescription pharmaceutical products that make a meaningful difference in patients’ lives throughout more than 100 countries. Valeant’s primary focus is in the areas of dermatology and eye health.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MORGAN STANLEY GIVES VALEANT PHARMACEUTICALS PRICE TARGET WITH POTENTIAL 27.93% UPSIDE

Uk Market News | December 16, 2016

news image

On Thursday Morgan Stanley downgraded its target price on Valeant Pharmaceuticals (NYSE:VRX) shares issuing the company with a ‘Equal-Weight’ rating....

Read More

VALEANT PHARMACEUTICALS ANNOUNCES ADDITION OF RICHARD U. DESCHUTTER TO ITS BOARD OF DIRECTORS

Pharmaceuticals | January 04, 2017

news image

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that the Board of Directors has elected Richard (Dick) U. DeSchutter to serve as a director, effective January 2, 2017. With the addition of Mr. DeSchutter, Valeant has increased the size of its Board to 13 members, 12 of whom are independent....

Read More

VALEANT PHARMACEUTICALS (VRX) MAKES MONSTER PROFITS FROM EARLY 2017 DISPOSALS

Learn Bonds | January 16, 2017

news image

Forging into 2017, analysts continue to cite Valeant Pharmaceutical Intl. Inc.’s (NYSE:VRX) debt, public image and reduced influence among its biggest challenges. The drug maker is now set on regaining portions of the confidence it lost during the last two years. Valeant shares rose to great peaks back in July 2015. A number of setbacks have since gradually chipped away at its all-time highs, and persist to the current day....

Read More

COMPANY UPDATE (NYSE:VRX): VALEANT PHARMACEUTICALS INTL INC ANNOUNCES DEPLOYMENT OF EXPANDED SALIX SALES FORCE TO CAPTURE UNTAPPED MARKET OPPORTUNITY

Smarter analyst | February 27, 2017

news image

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced that it has rapidly scaled up its sales force by nearly 40 percent, effective immediately. “This is a demonstration of our commitment to GI and its relative importance to the broader value of our company,” said Joseph C. Papa, Chairman and CEO of Valeant. “The significant investments in Salix’s dedicated Primary Care Physician (PCP) sales force will help us further reach patients in need of irritable bowel syndrome with diarrhea (IBS-D) trea...

Read More
news image

MORGAN STANLEY GIVES VALEANT PHARMACEUTICALS PRICE TARGET WITH POTENTIAL 27.93% UPSIDE

Uk Market News | December 16, 2016

On Thursday Morgan Stanley downgraded its target price on Valeant Pharmaceuticals (NYSE:VRX) shares issuing the company with a ‘Equal-Weight’ rating....

Read More
news image

VALEANT PHARMACEUTICALS ANNOUNCES ADDITION OF RICHARD U. DESCHUTTER TO ITS BOARD OF DIRECTORS

Pharmaceuticals | January 04, 2017

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that the Board of Directors has elected Richard (Dick) U. DeSchutter to serve as a director, effective January 2, 2017. With the addition of Mr. DeSchutter, Valeant has increased the size of its Board to 13 members, 12 of whom are independent....

Read More
news image

VALEANT PHARMACEUTICALS (VRX) MAKES MONSTER PROFITS FROM EARLY 2017 DISPOSALS

Learn Bonds | January 16, 2017

Forging into 2017, analysts continue to cite Valeant Pharmaceutical Intl. Inc.’s (NYSE:VRX) debt, public image and reduced influence among its biggest challenges. The drug maker is now set on regaining portions of the confidence it lost during the last two years. Valeant shares rose to great peaks back in July 2015. A number of setbacks have since gradually chipped away at its all-time highs, and persist to the current day....

Read More
news image

COMPANY UPDATE (NYSE:VRX): VALEANT PHARMACEUTICALS INTL INC ANNOUNCES DEPLOYMENT OF EXPANDED SALIX SALES FORCE TO CAPTURE UNTAPPED MARKET OPPORTUNITY

Smarter analyst | February 27, 2017

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced that it has rapidly scaled up its sales force by nearly 40 percent, effective immediately. “This is a demonstration of our commitment to GI and its relative importance to the broader value of our company,” said Joseph C. Papa, Chairman and CEO of Valeant. “The significant investments in Salix’s dedicated Primary Care Physician (PCP) sales force will help us further reach patients in need of irritable bowel syndrome with diarrhea (IBS-D) trea...

Read More